**Executive Summary**
On March 17, 2026, the Technology Development Board (TDB) of the Department of Science & Technology announced financial assistance for Acrannolife Genomics Private Limited to establish a state-of-the-art manufacturing facility in Chennai. The project aims to scale up the indigenous production of "Trunome GrafAssure" and "TBFYND" in-vitro diagnostic (IVD) kits at the TANSIDCO Industrial Estate. This initiative is designed to strengthen India’s domestic molecular diagnostics capabilities and reduce reliance on imported medical technologies.
**Key Points / Main Content**
**Project Objectives and Infrastructure**
* **Facility Establishment:** The project focuses on creating an advanced manufacturing facility to support large-scale production and deployment of indigenous IVD solutions.
* **Strategic Location:** The facility will be located at the TANSIDCO Industrial Estate to drive scalable and sustainable growth.
* **Self-Reliance:** The initiative aims to promote self-reliance in critical medical technologies and transition cutting-edge research into affordable healthcare.
**Product Specifications**
* **Trunome GrafAssure:** A flagship blood test for the early detection of post-transplant organ rejection and infection. It uses cell-free DNA analysis to identify issues weeks before clinical symptoms appear.
* **TBFYND:** A diagnostic kit developed for the rapid and accurate detection of tuberculosis, addressing a major public health challenge in India.
* **Proprietary Technology:** Both kits are developed in-house with secured intellectual property and utilize a proprietary software platform for scalable workflows.
**Technological Framework**
* **Platforms:** The diagnostics are based on cell-free DNA and LAMP technology platforms.
* **Non-Invasive Focus:** The company specializes in innovative, non-invasive technologies for infectious diseases and transplant diagnostics.
**Impact Analysis**
**Acrannolife Genomics Private Limited**
* **Impact:** Receives financial backing to transition from laboratory development to large-scale industrial manufacturing.
* **Action Required:** Establish the manufacturing facility and scale up the production and deployment of the Trunome GrafAssure and TBFYND diagnostic kits.
**Healthcare Providers and Clinicians**
* **Impact:** Gain access to high-sensitivity diagnostic tools that enable earlier medical intervention and improved patient outcomes.
* **Action Required:** Incorporate these indigenous genomic diagnostics into clinical workflows for transplant monitoring and tuberculosis screening.
**Technology Development Board (TDB) / Government**
* **Impact:** Advances the mandate of supporting indigenous biotechnological innovations and strengthening the national healthcare ecosystem.
* **Action Required:** Provide the promised financial assistance and oversee the project's contribution toward reducing import dependence.
**Patients (Transplant and Tuberculosis Patients)**
* **Impact:** Benefit from increased access to innovative, affordable, and timely diagnostic solutions.
* **Action Required:** Utilize these advanced diagnostic tests for early detection and management of medical conditions as prescribed by healthcare providers.
Key Entities Referenced
Technology Development Board (TDB): A statutory body under the Department of Science & Technology providing financial assistance for the commercialization and indigenous manufacturing of innovative technologies.
Acrannolife Genomics Private Limited, Chennai: A biotechnology company supported to establish an advanced manufacturing facility at the TANSIDCO Industrial Estate for indigenous in-vitro diagnostic (IVD) solutions.
Trunome GrafAssure: A flagship diagnostic blood test developed for the early detection of post-transplant organ rejection and infection.
TBFYND: An indigenous diagnostic kit designed for the rapid and accurate detection of tuberculosis, addressing a major public health challenge in India.
Department of Science & Technology (DST): The central government department that, through the TDB, facilitates the scaling up of indigenous medical technologies and molecular diagnostics.
Ministry of Science & Technology
“TDB-DST supports Acrannolife Genomics
Private Limited, Chennai for Indigenous
Manufacturing of Advanced IVD Diagnostic Kits”
Posted On: 17 MAR 2026 4:45PM by PIB Delhi
The Technology Development Board (TDB), Department of Science & Technology (DST), Government
of India, has extended financial assistance to Acrannolife Genomics Private Limited, Chennai for the
project titled “Indigenizing IVD Innovation: Establishing a State-of-the-Art Manufacturing Facility to
Drive Scalable and Sustainable Growth of Trunome GrafAssure IVD Kits and TBFYND IVD Kits.” The
project focuses on establishing an advanced manufacturing facility to support the large-scale production
and deployment of indigenous in-vitro diagnostic (IVD) solutions developed by the company.
Acrannolife Genomics Private Limited is engaged in developing innovative non-invasive diagnostic
technologies based on cell-free DNA and LAMP technology platforms, addressing critical healthcare
needs such as infectious diseases and transplant diagnostics. Through this project, the company will
establish a state-of-the-art manufacturing facility at the TANSIDCO Industrial Estate to scale up
production of two key diagnostic products—Trunome GrafAssure and TBFYND.
The company’s flagship product, Trunome GrafAssure, is a laboratory-developed blood test designed for
the early detection of post-transplant organ rejection and infection in patients who have undergone solid-
organ transplants. The test utilizes advanced cell-free DNA analysis to provide high diagnostic sensitivity
and specificity, enabling clinicians to detect signs of rejection or infection weeks before clinical symptoms
appear, thereby supporting timely medical intervention and improved patient outcomes.
The second product, TBFYND, is designed to address the urgent need for rapid and accurate detection of
tuberculosis, one of the most significant public health challenges in India. Both diagnostic kits are fully
developed in-house with secured intellectual property and will be processed through the company’s
proprietary software platform, ensuring reliable and scalable diagnostic workflows.
With support from TDB, the project will enable the creation of a dedicated platform facility for
manufacturing these IVD kits at scale, strengthening India’s domestic capabilities in molecular diagnostics
and reducing dependence on imported diagnostic technologies.
Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated that the Board remains
committed to supporting indigenous biotechnological innovations that translate cutting-edge research into
affordable and accessible healthcare solutions. He noted that the establishment of advanced manufacturing
capabilities for diagnostic technologies will play a vital role in strengthening India’s healthcare ecosystem
and promoting self-reliance in critical medical technologies.
Promoters of Acrannolife Genomics Private Limited expressed appreciation for the support extended by
TDB and highlighted that the assistance will enable the company to scale up production, accelerate
deployment of its diagnostic kits, and expand access to innovative genomic diagnostics for patients and
healthcare providers.********
NKR/FT
(Release ID: 2241259) Visitor Counter : 182
Read this release in: ही , Urdu